Brain Tumor Res Treat.  2022 Apr;10(2):83-93. 10.14791/btrt.2022.0001.

The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO

• Kim YZ
• Kim CY
• Lim DH

• KMID: 2529439
• DOI: http://doi.org/10.14791/btrt.2022.0001

Abstract

Gliomas have been histologically diagnosed as the third most common primary tumor of the central nervous system (CNS) in a relatively small portion of Korea. Despite the rarity of gliomas, the disease entity is very dynamic due to its various molecular characteristics, compared with other CNS tumors. The practice of managing glioma patients is not globally established as a precise standard guideline because of the different socio-medical environments of individual countries. The Korean Society for Neuro-Oncology (KSNO) published guidelines for managing adult glioma in 2019, and the National Comprehensive Cancer Network and European Association of Neuro-Oncology published guidelines in September 2021 and March 2021, respectively. However, these guidelines have several different recommendations in practice, including tissue management, adjuvant treatment after surgical resection, and salvage treatment for recurrent/progressive gliomas. Currently, the KSNO guideline working group is preparing an updated version of the guideline for managing adult gliomas. In this review, common features have been verified and different points are analyzed. Consequently, this review is expected to be informative and helpful to provide high quality evidence and a strong recommendation level for the establishment of new KSNO guidelines for managing gliomas.

Keyword

Guideline; Gliomas; KSNO; Practice

Reference

1. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23(Suppl 3):iii1–iii105. PMID: 34608945.

2. Dho YS, Jung KW, Ha J, Seo Y, Park CK, Won YJ, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017; 5:16–23. PMID: 28516074.

3. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23:1231–1251. PMID: 34185076.

4. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, et al. cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2017; 27:851–852. PMID: 27997995.

5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131:803–820. PMID: 27157931.

6. Kim YZ, Kim CY, Lim J, Sung KS, Lee J, Oh HJ, et al. The Korean Society for Neuro-Oncology (KSNO) guideline for glioblastomas: version 2018.01. Brain Tumor Res Treat. 2019; 7:1–9. PMID: 31062525.

7. Kim YZ, Kim CY, Lim J, Sung KS, Lee J, Oh HJ, et al. The Korean Society for Neuro-Oncology (KSNO) guideline for WHO grade III cerebral gliomas in adults: version 2019.01. Brain Tumor Res Treat. 2019; 7:63–73. PMID: 31686436.

8. Kim YZ, Kim CY, Wee CW, Roh TH, Hong JB, Oh HJ, et al. The Korean Society for Neuro-Oncology (KSNO) guideline for WHO grade II cerebral gliomas in adults: version 2019.01. Brain Tumor Res Treat. 2019; 7:74–84. PMID: 31686437.

9. National Comprehensive Cancer Netowrk. NCCN guidelines; central nervous system cancers. Version 2.2021. Plymouth Meeting: National Comprehensive Cancer Network;2021. Accessed December 1, 2021. at https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425.

10. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021; 18:170–186. PMID: 33293629.

11. Williams M, Treasure P, Greenberg D, Brodbelt A, Collins P. Surgeon volume and 30 day mortality for brain tumours in England. Br J Cancer. 2016; 115:1379–1382. PMID: 27764843.

12. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987–996. PMID: 15758009.

13. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27:4733–4740. PMID: 19720927.

14. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27:740–745. PMID: 19114704.

15. Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022; 40:403–426. PMID: 34898238.